Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
37767Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338211068965. doi: 10.1177/15330338211068965.
Worldwide breast cancer ranks first in mortality and incidence rates in women over 20 years old. Rather than one disease, breast cancer is a heterogeneous group of diseases that express distinct molecular profiles. Neoadjuvant chemotherapy is an important therapeutic strategy for breast cancer patients independently of their molecular subtype, with the drawback of resistance development. In addition, chemotherapy has adverse effects that combined with resistance could contribute to lower overall survival. Although great efforts have been made to find diagnostic and prognostic biomarkers for breast cancer and for response to targeted and immune therapy for this pathology, little has been explored regarding biomarkers of response to anthracyclines and taxanes based neoadjuvant chemotherapy. This work aimed to evaluate the molecular profile of patients who received neoadjuvant chemotherapy to identify differentially expressed genes (DEGs) that could be used as biomarkers of chemotherapy response and overall survival. Breast cancer patients who were candidates for neoadjuvant chemotherapy were enrolled in this study. After treatment and according to their pathological response, they were assigned as sensitive or resistant. To evaluate DEGs, Gene Ontology, Kyoto Encyclopedia Gene and Genome (KEGG), and protein-protein interactions, RNA-seq information from all patients was obtained by next-generation sequencing. A total of 1985 DEGs were found, and KEGG analysis indicated a great number of DEGs in metabolic pathways, pathways in cancer, cytokine-cytokine receptor interactions, and neuroactive ligand-receptor interactions. A selection of 73 DEGs was used further for an analysis of overall survival using the METABRIC study and the ductal carcinoma dataset of The Cancer Genome Atlas (TCGA) database. Nine DEGs correlated with overall survival, of which the subexpression of and the overexpression of and were found in resistant patients and related to patients with lower overall survival.
全球范围内,乳腺癌在 20 岁以上女性中的死亡率和发病率均位居首位。乳腺癌并非一种单一的疾病,而是一组具有不同分子特征的异质性疾病。新辅助化疗是一种重要的治疗策略,适用于所有分子亚型的乳腺癌患者,但存在耐药性发展的缺点。此外,化疗还具有不良反应,与耐药性相结合可能导致总体生存率降低。尽管人们已经做出了巨大努力来寻找乳腺癌的诊断和预后生物标志物以及针对该病理学的靶向和免疫治疗反应的生物标志物,但对于基于蒽环类和紫杉烷类的新辅助化疗反应的生物标志物的研究却很少。本研究旨在评估接受新辅助化疗的患者的分子谱,以确定可作为化疗反应和总体生存率的生物标志物的差异表达基因(DEGs)。本研究纳入了适合接受新辅助化疗的乳腺癌患者。根据治疗后的病理反应,将患者分为敏感组或耐药组。为了评估 DEGs,通过下一代测序获得了所有患者的 RNA-seq 信息,进行了基因本体论(GO)、京都基因与基因组百科全书(KEGG)和蛋白质-蛋白质相互作用分析。共发现 1985 个 DEGs,KEGG 分析表明代谢途径、癌症途径、细胞因子-细胞因子受体相互作用和神经活性配体-受体相互作用中有大量 DEGs。选择 73 个 DEGs 进一步使用 METABRIC 研究和癌症基因组图谱(TCGA)数据库的导管癌数据集分析总生存率。有 9 个 DEGs 与总生存率相关,其中在耐药患者中发现了和的亚表达以及和的过表达与患者的总体生存率较低相关。